OBJECTIVE: To investigate the clinical efficacy and immune mechanism of immunotherapy of dendritic cells (DC) and cytokine-induced killer cell (CIK) combined with chemotherapy in @entity1 with newly diagnosed @entity1582 ( @entity1582 ). METHODS: twenty-two newly diagnosed @entity1582 @entity1 were chosen and divided into two groups, out of them,12 @entity1 in single chemotherapy group were treated by chemotherapy only, 10 @entity1 in combined group were treated by adoptive immunotherapy (DC-CIK) combined with chemotherapy. Using flow cytometry, the @entity404 Treg cells in the peripheral blood of 22 @entity1582 @entity1 were detected before and after treatment. And the clinical outcomes between two groups were also compared. RESULTS: After treatment the overall response rate(ORR) of @entity1 in the single chemotherapy group was 50% (6/12), among them 2 cases were in complete remission (CR) (16.67%), 2 cases very good partial remission (VGPR) (16.67%), 2 cases were in partial remission (PR) (16.67%). However, the ORR of @entity1 in immunotherapy combined with chemotherapy group was 70.% (7/10), including in 3 cases of CR (30%), 2 cases of VGPR (20%), 2 cases of PR (20%). Compared to healthy volunteers, the proportion of Treg cells in peripheral blood of two groups before treatment was significantly higher (P < 0.05). In contrast, the proportion of Treg cells in the peripheral blood of above-mentioned 2 groups after treatment was reduced significantly (P < 0.05). In addition, compared to chemotherapy group, the proportion of Treg cells in the combined group decreased significantly (P < 0.05). The further analysis found that the proportion of Treg cells in the peripheral blood of the 2 groups was not significant changed (P > 0.05) in the @entity1 with ineffictive clinical treatment, but the proportion of Treg cells significantly decreased (P < 0.05) in the @entity1 with effective clinical treatment. CONCLUSION: DC-CIK immunotherapy can synergize or enhance the effect of chemotherapeutics, alleviate the @entity1200 in @entity1582 ; and DC-CIK immunotherapy combined with chemotherapy can elevate the clinical efficacy in @entity1 with newly diagnosed @entity1582 .

[Clinical Efficacy of DC and CIK Immunotherapy Combined with Chemotherapy and Its Impact on Treg Cells in Newly Diagnosed XXXX ].

@entity1 :: ('9606', 'Species') :: ['patients'] @entity1582 :: ('MESH:D009101', 'Disease') :: ['multiple myeloma', 'MM'] @entity404 :: ('920', 'Gene') :: ['CD4'] @entity1200 :: ('MESH:D007154', 'Disease') :: ['immune dysfunction']
@entity1582 :: (MESH:D009101,Disease) :: ['Multiple Myeloma']
